The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease
Cytometry Part B: Clinical Cytometry · 2023
DOI: 10.1002/cyto.b.22118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2023. Verfasst von Fan-Chi Hsu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematologics, Inc., Seattle, Washington, USA. Hauptthemen laut MEDLINE: Down Syndrome, Leukemia, Myeloid, Acute, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Detection of measurable residual disease detection (MRD) by flow cytometry after the first course of chemotherapy is a standard measure of early response in patients with acute myeloid leukemia (AML). Myeloid leukemia associated with Down Syndrome (ML‐DS) is a distinct form of AML. Differences in steady‐state and regenerating hematopoiesis between patients with or without DS are not well understood. This understanding is essential to accurately determine the presence of residual leukemia in patients with ML‐DS.
Methods
A standardized antibody panel defined quantitative antigen expression in 115 follow‐up bone marrow (BM) aspirates from 45 patients following chemotherapy for ML‐DS or DS precursor B‐cell acute lymphoblastic leukemia (B‐ALL‐DS) with the “difference from normal (Δ N )” technique. When possible, FISH and SNP/CGH microarray studies were performed on sorted cell fractions.
Results
93% of BM specimens submitted post chemotherapy had a clearly identifiable CD34 + CD56 + population present between 0.06% and 2.6% of total non‐erythroid cells. An overlapping CD34 + HLA‐DR heterogeneous population was observed among 92% of patients at a lower frequency (0.04%–0.8% of total non‐erythroid cells). In B‐ALL‐DS patients, the same CD34 + CD56 + HLA‐DR heterogeneous expression was observed. FACS‐FISH/Array studies demonstrated no residual genetic clones in the DS‐specific myeloid progenitor cells.
Conclusions
Non‐malignant myeloid progenitors in the regenerating BM of patients who have undergone chemotherapy for either ML‐DS or B‐ALL‐DS express an immunophenotype that is different from normal BM of non‐DS patients. Awareness of this DS‐specific non‐malignant myeloid progenitor is essential to the interpretation of MRD by flow cytometry in patients with ML‐DS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematologics, Inc., Seattle, Washington, USA.
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
- The Hospital for Sick Children, Toronto, Ontario, Canada.
- CHEO Research Institute, Ottawa, Ontario, Canada.
- University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Fan-Chi Hsu
Zitieren
APA
Hsu, F. C., Hudson, C., Wilson, E. R., Pardo, L. M., Singleton, T. P., Xu, D., Zehentner, B. K., Hitzler, J., Berman, J., Wells, D. A., Loken, M. R., & Brodersen, L. E. (2023). The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22118
Vancouver
Hsu FC, Hudson C, Wilson ER, Pardo LM, Singleton TP, Xu D, et al. The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. Cytometry Part B: Clinical Cytometry. 2023. doi:10.1002/cyto.b.22118
BibTeX
@article{Hsu2023,
author = {Hsu, Fan-Chi and Hudson, Chad and Wilson, Elisabeth R and Pardo, Laura M and Singleton, Timothy P and Xu, Dongbin and Zehentner, Barbara K and Hitzler, Johann and Berman, Jason and Wells, Denise A and Loken, Michael R and Brodersen, Lisa Eidenschink},
title = {The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2023},
doi = {10.1002/cyto.b.22118}
}
EUVIMED